Pharmaceutical Business review

Innovus introduces premature ejaculation drug EjectDelay in US

EjectDelay is an US Food and Drug Administration (FDA) and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation.

According to the company, the drug typically works within minutes of application to the glans of the penis.

In clinical trials, the application of benzocaine has been demonstrated to delay premature ejaculation by several minutes.

The company said that the product is available online through its website and the product’s specific website (www.ejectdelay.com).

Currently, the company is working with its US co-promotion partner for EjectDelay, Consortia Health, to place this product into urologists’ offices throughout the US.

The product will also be available in the future through Consortia Health’s website, it is available in two sizes in the US as a 2 ounce tube with a retail price of $19.99 and as a 5mL single use packet with a retail price of $2.99.

The EjectDelay product license has been approved in Canada and the company intends to launch the product in the Canadian market in 2014.